Ipsen Biopharmaceuticals, Inc.

510 articles with Ipsen Biopharmaceuticals, Inc.

• Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance

  10/22/2020

  Ipsen, a global specialty-driven biopharmaceutical group, announced sales for the third quarter of 2020.

• Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13

  10/8/2020

  Ipsen announced the presentation of 12 abstracts during the 11th World Congress for Neurorehabilitation, taking place virtually between 7-11 October 2020.1-13

• Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

  9/25/2020

  Ipsen announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020.

• ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial

  9/19/2020

  Cabometyx® in combination with Opdivo® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile

• ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months

  9/18/2020

  Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs

• Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress

  9/14/2020

  17 abstracts1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs

• Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results

  9/10/2020

  Seven presentations represent Ipsen’s largest presence to date at ASBMR, the world’s leading scientific organization for bone health research

• 

  BioSpace Global Roundup, Aug. 27

  8/27/2020

  Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.

• Ipsen Presents Its Half Year 2020 Results and Reinstates Guidance for Full Year 2020

  7/30/2020

  Ipsen, a global specialty-driven biopharmaceutical group, announced financial results for the first half of 2020.

• Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

  7/9/2020

  Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients

• Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer

  7/2/2020

  Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib

• Ipsen Initiates a Share Buyback Program to Cover Its Share Allocation Plan

  6/8/2020

  Ipsen, announces that it has appointed an investment services provider to purchase 450,000 Ipsen SA shares, or about 0.54% of the share capital, over a maximum period of 6 months.

• Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society

  6/8/2020

  Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression

• Ipsen Appoints David Loew as Chief Executive Officer

  5/29/2020

  Ipsen announced that its Board of Directors has appointed David Loew as its new Chief Executive Officer and as Board member.

• 

  Ipsen Taps Sanofi Vaccines Head David Loew as New CEO

  5/29/2020

  After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.

• Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

  5/23/2020

  Over 400 patients with spasticity or cervical dystonia responded to online surveys evaluating the disease burden and the impact on their personal and professional lives

• Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

  5/4/2020

  Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.

• Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact

  4/22/2020

  Continued momentum with Q1 2020 Group sales growth of 9.6% as reported, or 8.7%1 at constant exchange rates

• Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma

  4/20/2020

  Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib CABOMETYX in combination with Opdivo demonstrates clinically m

• Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19

  4/1/2020

  The biopharmaceutical group Ipsen has answered call of the Institut Pasteur and announces a donation of €2 million dedicated to COVID-19 research.